Dr. Thomas P. Archer, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- Ohio State University College of Medicine (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,834
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Ohio State University College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
OH license 35065935A -
Adult Congenital Heart Disease Physician
OH license 35065935A -
Advanced Heart Failure and Transplant Cardiology Physician
OH license 35065935A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sarasota Memorial Hospital Sarasota, FL
- Sarasota Memorial Hospital - Venice North Venice, FL
Medical groups
- Heart Specialists of Sarasota Pl (26 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,834
- Services billed
- 5,724
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,474 | 909 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,292 | 830 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 859 | 329 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 796 | 769 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 453 | 441 |
| New patient office or other outpatient visit, 45-59 minutes | 169 | 169 |
| Heart muscle strain imaging | 99 | 99 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 79 | 77 |
| Ultrasound of heart with probe in esophagus, with report | 76 | 76 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 75 | 75 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Metoprolol Succinate Other prescribers in Westerville, OH | 912 |
| Eliquis (apixaban) Other prescribers in Westerville, OH | 709 |
| Atorvastatin Calcium Other prescribers in Westerville, OH | 467 |
| Losartan Potassium Other prescribers in Westerville, OH | 436 |
| Rosuvastatin Calcium Other prescribers in Westerville, OH | 418 |
| Amlodipine Besylate Other prescribers in Westerville, OH | 244 |
| Spironolactone Other prescribers in Westerville, OH | 235 |
| Entresto (sacubitril/valsartan) Other prescribers in Westerville, OH | 217 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Westerville, OH | 214 |
| Furosemide Other prescribers in Westerville, OH | 208 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 77 payments worth $5,803 in total to this clinician.
| Cvrx, Inc. | $4,715 |
|---|---|
| Novartis Pharmaceuticals Corporation | $251 |
| Abiomed | $181 |
| Zoll Services LLC (a/k/a Zoll Lifecor Corp) | $172 |
| Pfizer Inc. | $121 |
| Abbott Laboratories | $70.10 |
| Bridgebio Pharma, Inc. | $58.37 |
| E.r. Squibb & Sons, L.l.c. | $51.17 |
| Consulting Fee | $2,850 |
|---|---|
| Food and Beverage | $2,125 |
| Travel and Lodging | $828 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Cvrx, Inc. Dec 17, 2025 | Consulting Fee Barostim Neo System · Heart Failure and Hypertension | $2,850 |
| Cvrx, Inc. Feb 13, 2025 | Travel and Lodging Barostim Neo System · Heart Failure and Hypertension · travel to New York, NY | $391 |
| Cvrx, Inc. Mar 17, 2025 | Travel and Lodging Barostim Neo System · Heart Failure and Hypertension · travel to New York, NY | $266 |
| Cvrx, Inc. Apr 21, 2025 | Travel and Lodging Barostim Neo System · Heart Failure and Hypertension · travel to New York, NY | $171 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $22,579 in research payments for these studies, mostly to the institutions running them.
- Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)
Cvrx, Inc. · Terminated · NCT04502316
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.